OBJECTIVE: To study the clinical implications of death-associated protein kinase (DAPK) promoter methylation and DAPK gene expression in untreated patients with acute leukemia. METHODS: Methylation-specific PCR and RT-PCR were employed to detect the DAPK gene methylation and mRNA expression in the bone marrow of 60 patients with acute myeloid leukemia (AML), 55 patients with acute lymphocytic leukemia (ALL), and 17 normal subjects. RESULTS: The positivity rate of DAPK methylation was significantly higher in ALL patients (29.1%) than in AML patients group (5%) and normal subjects (0%) (P<0.01). No correlation was found between DAPK gene methylation and the clinical features in ALL patients (P>0.05). DAPK mRNA expression level differed significantly among the 3 groups (P=0.000), and was the highest in normal subjects and the lowest in ALL patients. In ALL patients, the expression level of DAPK mRNA showed a significant inverse correlation with DAPK promoter methylation (P<0.05). CONCLUSION: The methylation rate of DAPK gene is higher in untreated ALL patients than in AML patients and normal subjects. DAPK gene methylation is not correlated with the clinical features of ALL patients but is probably related with the low gene expression level of DAPK in these patients.
OBJECTIVE: To study the clinical implications of death-associated protein kinase (DAPK) promoter methylation and DAPK gene expression in untreated patients with acute leukemia. METHODS: Methylation-specific PCR and RT-PCR were employed to detect the DAPK gene methylation and mRNA expression in the bone marrow of 60 patients with acute myeloid leukemia (AML), 55 patients with acute lymphocytic leukemia (ALL), and 17 normal subjects. RESULTS: The positivity rate of DAPK methylation was significantly higher in ALL patients (29.1%) than in AMLpatients group (5%) and normal subjects (0%) (P<0.01). No correlation was found between DAPK gene methylation and the clinical features in ALL patients (P>0.05). DAPK mRNA expression level differed significantly among the 3 groups (P=0.000), and was the highest in normal subjects and the lowest in ALL patients. In ALL patients, the expression level of DAPK mRNA showed a significant inverse correlation with DAPK promoter methylation (P<0.05). CONCLUSION: The methylation rate of DAPK gene is higher in untreated ALL patients than in AMLpatients and normal subjects. DAPK gene methylation is not correlated with the clinical features of ALL patients but is probably related with the low gene expression level of DAPK in these patients.
Authors: Marcelo L Larramendy; Tarja Niini; Erkki Elonen; Bálint Nagy; Juha Ollila; Mauno Vihinen; Sakari Knuutila Journal: Haematologica Date: 2002-06 Impact factor: 9.941
Authors: Rainer Claus; Björn Hackanson; Anna R Poetsch; Manuela Zucknick; Miriam Sonnet; Nadja Blagitko-Dorfs; Jan Hiller; Stefan Wilop; Tim H Brümmendorf; Oliver Galm; Uwe Platzbecker; John C Byrd; Konstanze Döhner; Hartmut Döhner; Michael Lübbert; Christoph Plass Journal: Int J Cancer Date: 2011-11-28 Impact factor: 7.396
Authors: Khaldon Bodoor; Yazan Haddad; Asem Alkhateeb; Abdullah Al-Abbadi; Mohammad Dowairi; Ahmad Magableh; Nazzal Bsoul; Abdulhameed Ghabkari Journal: Asian Pac J Cancer Prev Date: 2014
Authors: Ilse Van der Auwera; Catherine Bovie; Cecilia Svensson; Xuan B Trinh; Ridha Limame; Peter van Dam; Steven J van Laere; Eric A van Marck; Luc Y Dirix; Peter B Vermeulen Journal: BMC Cancer Date: 2010-03-12 Impact factor: 4.430
Authors: Viktoriya B Boncheva; Michael Linnebacher; Said Kdimati; Hannah Draper; Laurence Orchard; Ken I Mills; Gerald O'Sullivan; Mark Tangney; Barbara-Ann Guinn Journal: Biomolecules Date: 2022-07-29